PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12937038-8 2003 Preterm infants required higher doses of enoxaparin than full term infants to maintain anti-(factor Xa) levels in the target range (2.1 v 1.7 mg/kg/12 h). Enoxaparin 41-51 coagulation factor X Homo sapiens 93-102 18838932-3 2008 However, little pharmacodynamic data are available for determining the appropriate dosing and monitoring (by anti-Factor Xa levels) of intravenous enoxaparin. Enoxaparin 147-157 coagulation factor X Homo sapiens 114-123 15559689-7 2004 Fondaparinux is a selective, synthetic factor Xa inhibitor that has been shown to significantly reduce the risk of VTE versus enoxaparin in patients undergoing surgery for hip fracture. Enoxaparin 126-136 coagulation factor X Homo sapiens 39-48 15091002-8 2004 Concentrations of enoxaparin achieved in prophylaxis (0.1-0.25 anti-FXa IU/ml) did not significantly modify these parameters. Enoxaparin 18-28 coagulation factor X Homo sapiens 68-71 15091002-11 2004 In the presence of enoxaparin concentrations equal to or higher than 0.8 anti-FXa IU/ml, the inhibition of thrombin generation was higher than 80%. Enoxaparin 19-29 coagulation factor X Homo sapiens 78-81 14576044-8 2004 These peptides (1 mg/300 g rat) neutralized 1 U/mL anti-Factor Xa activity of enoxaparin in rats within 1 to 2 minutes. Enoxaparin 78-88 coagulation factor X Homo sapiens 56-65 17554520-7 2007 Newborns required increased doses of enoxaparin to achieve therapeutic anti-FXa levels (mean 1.62[Symbol: see text]mg/kg per dose) compared with infants aged 2-12 months (mean 1.12 mg/kg per dose; p=0.0002). Enoxaparin 37-47 coagulation factor X Homo sapiens 76-79 17489664-1 2007 Enoxaparin is a low-molecular-weight heparin (LMWH) derivative that exerts its anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin 0-10 coagulation factor X Homo sapiens 155-164 12937038-9 2003 Infants with congenital heart disease (CHD) required less enoxaparin than those without CHD to maintain an anti-(factor Xa) level in the target range (1.7 v 2.1 mg/kg/12 h). Enoxaparin 58-68 coagulation factor X Homo sapiens 113-122 12040334-0 2002 Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Enoxaparin 124-134 coagulation factor X Homo sapiens 59-68 12040334-3 2002 PURPOSE: The purpose of our study was the determination of the impact of patient age, sex, body weight, and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in patients with ACS. Enoxaparin 191-201 coagulation factor X Homo sapiens 126-135 1963020-3 1990 However, the concentration of enoxaparin, measured by competitive binding assay, declined with the longer half-life of 60 min, and its anti-Factor IIa and anti-Factor Xa activities had half-lives of 40 and 275 min, respectively. Enoxaparin 30-40 coagulation factor X Homo sapiens 160-169 10728020-0 2000 Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization. Enoxaparin 0-10 coagulation factor X Homo sapiens 72-86 10728020-0 2000 Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization. Enoxaparin 0-10 coagulation factor X Homo sapiens 112-121 10728020-11 2000 CONCLUSION: We conclude that enoxaparin in plasma concentrations achieved routinely in clinical practice is able to: (1) inhibit tissue factor mediated extrinsic coagulation by preventing platelet surface prothrombinase assembly, and (2) inactivate platelet prothrombinase activity and resulting thrombin generation. Enoxaparin 29-39 coagulation factor X Homo sapiens 205-219 10728020-11 2000 CONCLUSION: We conclude that enoxaparin in plasma concentrations achieved routinely in clinical practice is able to: (1) inhibit tissue factor mediated extrinsic coagulation by preventing platelet surface prothrombinase assembly, and (2) inactivate platelet prothrombinase activity and resulting thrombin generation. Enoxaparin 29-39 coagulation factor X Homo sapiens 258-272 1658968-0 1991 Anti Xa activity and prothrombinase inhibition in patients treated with two different doses of enoxaparin in gynecologic surgery. Enoxaparin 95-105 coagulation factor X Homo sapiens 21-35 1658968-12 1991 The mechanism of intrinsic prothrombinase inhibition during prophylactic treatment with enoxaparin requires further investigation. Enoxaparin 88-98 coagulation factor X Homo sapiens 27-41 11668418-3 2001 Unfractionated heparin (UFH) as well as low molecular weight heparin (LMWH) (enoxaparin) inhibited the mitogenic effects of FXa, thrombin and fetal calf serum (FCS), but did not reduce mitogenesis induced by PDGF. Enoxaparin 77-87 coagulation factor X Homo sapiens 124-127 1963020-4 1990 These data may reflect more rapid clearance of longer chain molecules with anti-Factor IIa activity, or release by enoxaparin of an endogenous compound with anti-Factor Xa activity. Enoxaparin 115-125 coagulation factor X Homo sapiens 162-171 34884411-11 2021 Enoxaparin efficacy is reduced in severe NS and the dose should be adjusted to ideal body weight to achieve target anti-FXa activity. Enoxaparin 0-10 coagulation factor X Homo sapiens 120-123 34781984-0 2021 Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19. Enoxaparin 35-45 coagulation factor X Homo sapiens 55-64 34781984-2 2021 Dosing of Low Molecular Weight Heparin (LMWH) for thromboprophylaxis in patients with severe COVID-19 is subject to ongoing debate.In this brief report, we describe our study where we retrospectively examined the efficacy of standard- versus intermediate-dosing of enoxaparin in attaining and maintaining accepted prophylactic levels of anti-Factor Xa (anti-FXa) in critically ill patients with COVID-19.We collected data for all patients with confirmed COVID-19 who were treated with enoxaparin for thromboprophylaxis in a single Intensive Care Unit (ICU) in the United Kingdom between 31st March and 16th November 2020. Enoxaparin 265-275 coagulation factor X Homo sapiens 342-351 34781984-2 2021 Dosing of Low Molecular Weight Heparin (LMWH) for thromboprophylaxis in patients with severe COVID-19 is subject to ongoing debate.In this brief report, we describe our study where we retrospectively examined the efficacy of standard- versus intermediate-dosing of enoxaparin in attaining and maintaining accepted prophylactic levels of anti-Factor Xa (anti-FXa) in critically ill patients with COVID-19.We collected data for all patients with confirmed COVID-19 who were treated with enoxaparin for thromboprophylaxis in a single Intensive Care Unit (ICU) in the United Kingdom between 31st March and 16th November 2020. Enoxaparin 265-275 coagulation factor X Homo sapiens 358-361 34402789-7 2021 The 95% CI of the ratios of the geometric least squared means of anti-FXa activity was 96.28 - 102.65 IU/mL for Cmax and 100.67 - 105.15 hxIU/mL for the AUC0-t of Chemi Enoxaparin compared with those of Clexane, and for anti-FIIa activity, they were 86.65 - 96.73 IU/mL for the Cmax and 87.72 - 97.25 hxIU/mL AUC0-t, which met the criterion for bioequivalence. Enoxaparin 169-179 coagulation factor X Homo sapiens 70-73 35100448-1 2022 OBJECTIVE: To evaluate the effectiveness of a body mass index (BMI)-based enoxaparin prophylaxis dosing protocol at achieving target anti-factor Xa (anti-Xa) concentrations in the trauma population. Enoxaparin 74-84 coagulation factor X Homo sapiens 138-147 34733033-0 2021 Factor Xa Levels in Patients Receiving Prophylactic Enoxaparin Sodium in the Intensive Care Unit of an Academic Hospital. Enoxaparin 52-69 coagulation factor X Homo sapiens 0-9 34733033-1 2021 Background: The aim of this study was to determine the anti-factor Xa levels in patients receiving enoxaparin sodium for venous thromboembolism prophylaxis in the intensive care unit (ICU). Enoxaparin 99-116 coagulation factor X Homo sapiens 60-69 34733033-9 2021 Conclusion: A fixed prophylactic 40 mg dose of enoxaparin was associated with a high proportion of subprophylactic anti-factor Xa levels. Enoxaparin 47-57 coagulation factor X Homo sapiens 120-129 34733033-11 2021 How to cite this article: Baloo MM, Scribante J, Perrie H, Calleemalay D, Omar S. Factor Xa Levels in Patients Receiving Prophylactic Enoxaparin Sodium in the Intensive Care Unit of an Academic Hospital. Enoxaparin 134-151 coagulation factor X Homo sapiens 82-91 34078133-1 2021 BACKGROUND: Recommended prophylactic doses of enoxaparin (Lovenox) are associated with subprophylactic anti-Factor Xa (anti-Xa) levels. Enoxaparin 46-56 coagulation factor X Homo sapiens 108-117 34078133-1 2021 BACKGROUND: Recommended prophylactic doses of enoxaparin (Lovenox) are associated with subprophylactic anti-Factor Xa (anti-Xa) levels. Enoxaparin 58-65 coagulation factor X Homo sapiens 108-117 34655821-0 2022 Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin. Enoxaparin 123-133 coagulation factor X Homo sapiens 23-32 2556813-0 1989 The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Enoxaparin 89-100 coagulation factor X Homo sapiens 30-39 2556813-8 1989 These findings suggest that when enoxaparine is administered as a once daily subcutaneous injection, the 12 hour anti-factor Xa level should not exceed 0.2 units per ml to minimize bleeding and levels greater than 0.05 units per ml should be obtained to optimize efficacy. Enoxaparin 33-44 coagulation factor X Homo sapiens 118-127 33400099-8 2021 Either weight-based or twice-daily escalated enoxaparin dosing regimens appear effective at achieving target anti-factor Xa levels among hospitalized patients, and no safety events were noted. Enoxaparin 45-55 coagulation factor X Homo sapiens 114-123 33512867-0 2021 Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. Enoxaparin 0-10 coagulation factor X Homo sapiens 86-95 33512867-2 2021 Several small retrospective studies have suggested that infants and young children require higher enoxaparin doses to achieve therapeutic anti-factor Xa levels compared with adults. Enoxaparin 98-108 coagulation factor X Homo sapiens 143-152 33512867-4 2021 The primary objective was to ascertain the enoxaparin dose required to achieve an anti-factor Xa level of 0.5 to 1.0 U/mL among 4 age groups in a large cohort of infants and young children between 60 days and 5 years of age. Enoxaparin 43-53 coagulation factor X Homo sapiens 87-96 33512867-7 2021 An inverse relationship between enoxaparin dose needed to achieve therapeutic anti-factor Xa levels and patient age was noted, particularly in the first year of life. Enoxaparin 32-42 coagulation factor X Homo sapiens 83-92 33512867-9 2021 CONCLUSION: Infants and young children require higher doses of enoxaparin to achieve therapeutic anti-factor Xa levels compared with adults. Enoxaparin 63-73 coagulation factor X Homo sapiens 102-111 32888192-12 2021 CONCLUSIONS: Enoxaparin thromboprophylaxis administered by CII inhibited more prominently FXa and preserved better the AT level, compared with standard subcutaneous care. Enoxaparin 13-23 coagulation factor X Homo sapiens 90-93 33086312-0 2020 Low anti-Factor Xa level predicts 90-day Symptomatic Venous Thromboembolism in Surgical Patients Receiving Enoxaparin Prophylaxis: A Pooled Analysis of Eight Clinical Trials. Enoxaparin 107-117 coagulation factor X Homo sapiens 9-18 32391762-12 2020 Early initiation of enoxaparin anti-factor Xa assay-guided venous thromboembolism chemoprophylaxis has a comparable risk of ICH progression to fixed dosing in patients with TBI. Enoxaparin 20-30 coagulation factor X Homo sapiens 36-45 32624425-3 2020 We sought to evaluate variability of anti-factor Xa levels in a cohort of RC patients receiving perioperative enoxaparin prophylaxis. Enoxaparin 110-120 coagulation factor X Homo sapiens 42-51 33155833-4 2020 Of the 245 patients included, 86 (35.1%) required enoxaparin at 30 mg to achieve the goal anti-factor Xa trough level. Enoxaparin 50-60 coagulation factor X Homo sapiens 95-104 32045583-6 2020 The primary study outcome was peak anti-factor Xa levels in response to fixed or weight-tiered enoxaparin. Enoxaparin 95-105 coagulation factor X Homo sapiens 40-49 31986476-7 2020 Compared to healthy volunteers, trauma patients had lower levels of AT, elevated thrombin generation, and lower anti-FXa levels in response to enoxaparin. Enoxaparin 143-153 coagulation factor X Homo sapiens 117-120 31843692-0 2020 Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels Compared with Recommended Thromboprophylaxis and Rates of Clinically Evident Venous Thromboembolism in Surgical Oncology Patients. Enoxaparin 13-23 coagulation factor X Homo sapiens 41-50 31463801-12 2020 CONCLUSIONS: Our dosing scheme of 40 mg vs. 60 mg enoxaparin stratified according to BMI proved to be effective in reaching prophylactic anti-FXa activity in 83% of adolescent patients. Enoxaparin 50-60 coagulation factor X Homo sapiens 142-145 32559127-0 2020 Anti-Factor Xa Levels in Low-weight Surgical Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis: A Prospective Cohort Study. Enoxaparin 64-74 coagulation factor X Homo sapiens 5-14 32559127-3 2020 This study aimed to determine the rate of achieving a prophylactic peak anti-factor Xa (AFXa) level in low-weight surgical patients using enoxaparin 30 mg daily. Enoxaparin 138-148 coagulation factor X Homo sapiens 77-86 30698331-0 2019 An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays. Enoxaparin 53-63 coagulation factor X Homo sapiens 96-105 31116389-0 2019 Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics. Enoxaparin 95-105 coagulation factor X Homo sapiens 19-28 31112313-4 2019 OBJECTIVE: To evaluate peak anti-factor Xa (aFXa) levels in low-weight patients receiving enoxaparin for VTE prophylaxis. Enoxaparin 90-100 coagulation factor X Homo sapiens 33-42 30698331-1 2019 INTRODUCTION: Co-administration of enoxaparin and a direct oral factor Xa inhibitor (xabans: apixaban, edoxaban, rivaroxaban) could give rise to the problem of overlapping the anti-Xa activity when measuring direct oral anticoagulant (DOAC) levels. Enoxaparin 35-45 coagulation factor X Homo sapiens 64-73 29490713-9 2018 CONCLUSIONS: Enoxaparin doses required to achieve prophylactic anti-factor Xa concentrations in young children with CHD were consistently higher than the currently recommended prophylactic dosing regimens. Enoxaparin 13-23 coagulation factor X Homo sapiens 68-77 29626461-2 2018 Enoxaparin"s pharmacologic impact can be quantified by using anti-Factor Xa (aFXa) levels. Enoxaparin 0-10 coagulation factor X Homo sapiens 66-75 28736059-0 2018 Anti-Factor Xa measurements in acute care surgery patients to examine enoxaparin dose. Enoxaparin 70-80 coagulation factor X Homo sapiens 5-14 29490713-0 2018 Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD. Enoxaparin 30-40 coagulation factor X Homo sapiens 89-98 29490713-2 2018 We aimed to determine whether current enoxaparin dosing regimens effectively achieve anti-factor Xa concentrations within prophylactic goal ranges in this patient population. Enoxaparin 38-48 coagulation factor X Homo sapiens 90-99 28918992-0 2017 Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy: 2 different dosing regimens of enoxaparin. Enoxaparin 109-119 coagulation factor X Homo sapiens 0-14 29367044-0 2018 Trauma patients with lower extremity and pelvic fractures: Should anti-factor Xa trough level guide prophylactic enoxaparin dose? Enoxaparin 113-123 coagulation factor X Homo sapiens 71-80 29367044-11 2018 CONCLUSIONS: Prophylactic enoxaparin adjusted by anti-factor Xa level may lead to a decreased rate of clinically evident VTE among trauma patients with lower extremity and/or pelvic fractures. Enoxaparin 26-36 coagulation factor X Homo sapiens 54-63 28846877-0 2017 Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. Enoxaparin 95-105 coagulation factor X Homo sapiens 12-15 28846877-11 2017 CONCLUSIONS: Continuous infusion of enoxaparin led to lower anti-FXa Cmax24h than standard SCB administration. Enoxaparin 36-46 coagulation factor X Homo sapiens 65-68 28918992-13 2017 However, a multivariate analysis including enoxaparin dose found that only enoxaparin dose remained significantly correlated with anti-FXa levels. Enoxaparin 75-85 coagulation factor X Homo sapiens 135-138 27693871-0 2016 Supratherapeutic anti-factor Xa levels in patients receiving prophylactic doses of enoxaparin: A case series. Enoxaparin 83-93 coagulation factor X Homo sapiens 22-31 27936527-0 2017 Individualized dosing of enoxaparin in a morbidly obese patient by monitoring the anti-factor Xa. Enoxaparin 25-35 coagulation factor X Homo sapiens 87-96 27383732-0 2016 Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma. Enoxaparin 20-30 coagulation factor X Homo sapiens 55-64 27383732-2 2016 The VTE rate when enoxaparin sodium is dosed by anti-factor Xa (anti-Xa) trough level is not well described. Enoxaparin 18-35 coagulation factor X Homo sapiens 53-62 27440463-0 2016 Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. Enoxaparin 10-20 coagulation factor X Homo sapiens 46-49 28808492-0 2017 Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients. Enoxaparin 41-51 coagulation factor X Homo sapiens 19-28 28467656-4 2017 At approved doses, estimated odds ratios vs. both doses of enoxaparin for the three FXa inhibitors (range: 0.35-0.75 for VTE; 0.76-1.09 for bleeding) compared with those for dabigatran (range: 0.66-1.21 for VTE; 1.10-1.38 for bleeding) suggested generally greater efficacy and less bleeding for the FXa inhibitors. Enoxaparin 59-69 coagulation factor X Homo sapiens 84-87 27256341-0 2016 The use of anti-factor Xa monitoring in a selection of patients receiving enoxaparin at a large academic medical center. Enoxaparin 74-84 coagulation factor X Homo sapiens 16-25 27693871-2 2016 Real time anti-Factor Xa monitoring for surgical patients on enoxaparin prophylaxis is increasingly common. Enoxaparin 61-71 coagulation factor X Homo sapiens 15-24 27693871-3 2016 PRESENTATION OF CASES: We report on three cancer patients with therapeutic or supratherapeutic anti-Factor Xa levels while on prophylactic doses of enoxaparin after surgical procedures. Enoxaparin 148-158 coagulation factor X Homo sapiens 100-109 25325764-3 2015 The drug of choice is enoxaparin, due to its favorable FXa/FIIa ratio and the availability of pharmacokinetic and pharmacodynamic data. Enoxaparin 22-32 coagulation factor X Homo sapiens 55-58 25716128-2 2015 The objective of this study was to assess anti-factor Xa activity in adolescent bariatric surgical patients receiving prophylactic enoxaparin. Enoxaparin 131-141 coagulation factor X Homo sapiens 47-56 24335994-15 2014 CONCLUSION: The pharmacodynamics of a 30-minute IV enoxaparin infusion was found to produce therapeutic 4 hour anti-Factor Xa levels similar to subcutaneous doses. Enoxaparin 51-61 coagulation factor X Homo sapiens 116-125 24458050-1 2014 BACKGROUND: Low anti-factor Xa (anti-Xa) concentrations with twice-daily enoxaparin are associated with venous thromboembolism (VTE) in high-risk trauma patients. Enoxaparin 73-83 coagulation factor X Homo sapiens 21-30 25526009-1 2014 Enoxaparin sodium is a heparin of low molecular weight with antithrombotic properties that acts by inhibiting factor Xa. Enoxaparin 0-17 coagulation factor X Homo sapiens 110-119 24943261-7 2014 We evaluated how this change in anti-FXa assays influenced enoxaparin dosing (mg kg(-1) ). Enoxaparin 59-69 coagulation factor X Homo sapiens 37-40 23808469-4 2013 OBJECTIVE: To determine whether the direct thrombin inhibitors lepirudin and argatroban and the predominantly factor Xa inhibitors enoxaparin, danaparoid, and fondaparinux could interfere with LA screening based on dPT. Enoxaparin 131-141 coagulation factor X Homo sapiens 110-119 21526168-2 2011 Its mechanism of action is antithrombin independent and differs from that of other anticoagulants, such as warfarin (a vitamin K antagonist), enoxaparin (an indirect thrombin/Factor Xa inhibitor) and dabigatran (a direct thrombin inhibitor). Enoxaparin 142-152 coagulation factor X Homo sapiens 175-184 22040919-9 2011 In contrast, prothrombinase- and clot-induced prothrombin activation were resistant to inhibition by enoxaparin. Enoxaparin 101-111 coagulation factor X Homo sapiens 13-28 22048231-5 2011 The direct inhibitors of FXa, the activated form of factor X--also known as prothrombinase--were found to have a significantly higher TI than that of any other class of anticoagulants, including enoxaparin, suggesting that this mechanism of action provides the best safety-to-efficacy margin. Enoxaparin 195-205 coagulation factor X Homo sapiens 25-28 22048231-5 2011 The direct inhibitors of FXa, the activated form of factor X--also known as prothrombinase--were found to have a significantly higher TI than that of any other class of anticoagulants, including enoxaparin, suggesting that this mechanism of action provides the best safety-to-efficacy margin. Enoxaparin 195-205 coagulation factor X Homo sapiens 76-90 27121789-6 2013 The results showed that rivaroxaban (10 mg) and enoxaparin (40 mg) had a similar and rapid onset of action, as indicated by the similar anti-factor Xa activity-time curves, suggesting that both drugs have a similar duration of pharmacological activity at the factor X site. Enoxaparin 48-58 coagulation factor X Homo sapiens 141-150 23533746-4 2013 Rivaroxaban is one of the new oral anticoagulants and is a direct factor Xa inhibitor that has demonstrated superior efficacy to that of enoxaparin. Enoxaparin 137-147 coagulation factor X Homo sapiens 66-75 23227470-4 2012 WHAT THIS STUDY ADDS: The standard dose of 40 mg enoxaparin led to a significant increase in anti-FXa levels in this selected cohort of ICU patients with normal renal function. Enoxaparin 49-59 coagulation factor X Homo sapiens 98-101 23227470-10 2012 AIM: In critically ill patients, reduced anti-FXa plasma activity following subcutaneous administration of enoxaparin or nadroparin has been described. Enoxaparin 107-117 coagulation factor X Homo sapiens 46-49 23227470-16 2012 RESULTS: The anti-FXa plasma activity increased significantly after enoxaparin administration, with peak levels at 3 h after treatment, but was comparable between the ICU and medical ward groups (median 0.16 IU ml-1 [IQR 0-0.22 IU ml-1] vs. 0.2 IU ml-1 [IQR 0.15-0.27 IU ml-1],respectively, P = 0.13). Enoxaparin 68-78 coagulation factor X Homo sapiens 18-21 22876779-12 2012 For major bleeding during the prolonged treatment period, the RR was 2.69 (95% CI 1.65, 4.39) for patients treated with an FXa inhibitor compared with enoxaparin/placebo. Enoxaparin 151-161 coagulation factor X Homo sapiens 123-126 22876779-14 2012 CONCLUSION: In acute medically ill patients, prolonged thromboprophylaxis with an oral FXa inhibitor is more protective than regular short-term treatment with enoxaparin. Enoxaparin 159-169 coagulation factor X Homo sapiens 87-90 22876779-15 2012 However, treatment with FXa inhibitors is significantly associated with major bleeding, both in long- and short-term treatment compared with enoxaparin. Enoxaparin 141-151 coagulation factor X Homo sapiens 24-27 22565589-0 2012 Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Enoxaparin 32-42 coagulation factor X Homo sapiens 82-91 22565589-2 2012 We prospectively compared three enoxaparin dosing regimens for the achievement of goal peak anti-Factor Xa levels in medically ill patients (n 5 31) with extreme obesity (body mass index (BMI) 40 kg/m2). Enoxaparin 32-42 coagulation factor X Homo sapiens 97-106 22565589-9 2012 To our knowledge this is the first prospective comparative study demonstrating that in extremely obese, medically ill patients enoxaparin 0.5 mg/kg QDay is superior to FD and LD enoxaparin for the achievement of target anti-Factor Xa levels. Enoxaparin 127-137 coagulation factor X Homo sapiens 224-233 21409381-0 2011 Non-therapeutic anti-FXa levels are common among medical ward patients treated with enoxaparin. Enoxaparin 84-94 coagulation factor X Homo sapiens 21-24 21150227-2 2011 OBJECTIVE: To evaluate the anticoagulant effects of the two LMWHs nadroparin and enoxaparin on endogenous formation of FXa or FIIa in cord versus adult platelet-poor plasma (PPP) and on thrombelastometry profiles in cord versus adult whole blood (WB). Enoxaparin 81-91 coagulation factor X Homo sapiens 119-122 21083516-0 2011 Effects of enoxaparin preparations on thrombin generation and their correlation with their anti-FXa activity. Enoxaparin 11-21 coagulation factor X Homo sapiens 96-99 20972772-3 2011 In this study, a fluorogenic anti-FXa assay was developed using a commercially available fluorogenic substrate with an attached 6-amino-1-naphthalene-sulfonamide (ANSN) fluorophore and was used for the determination of two LMWHs, enoxaparin and tinzaparin and the heparinoid, danaparoid. Enoxaparin 230-240 coagulation factor X Homo sapiens 34-37 21150227-4 2011 METHODS: The effects of nadroparin, enoxaparin, or UH on endogenous formation of FXa or FIIa was investigated in tissue factor-activated PPP using a subsampling technique and chromogenic substrates. Enoxaparin 36-46 coagulation factor X Homo sapiens 81-84 21150227-6 2011 RESULTS: The major findings are (i) nadroparin is as efficient as enoxaparin concerning inhibition of the endogenous formation of FXa and FIIa, (ii) cord PPP and WB are significantly more susceptible to the addition of LMWHs or UH than adult PPP or WB, and (iii) compared by equivalent anti-FXa activity, the anticoagulant action of UH is markedly higher than that of the LMWHs in PPP and WB of neonatal or adult origin. Enoxaparin 66-76 coagulation factor X Homo sapiens 130-133 20870944-8 2010 Furthermore, FXa-induced cleavage of C3 was significantly suppressed in the presence of the selective FXa inhibitors fondaparinux and enoxaparin in a concentration-dependent manner. Enoxaparin 134-144 coagulation factor X Homo sapiens 13-16 21175312-2 2010 Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree. Enoxaparin 38-48 coagulation factor X Homo sapiens 71-80 20870944-8 2010 Furthermore, FXa-induced cleavage of C3 was significantly suppressed in the presence of the selective FXa inhibitors fondaparinux and enoxaparin in a concentration-dependent manner. Enoxaparin 134-144 coagulation factor X Homo sapiens 102-105 19850587-0 2010 FXa inhibition and coagulation changes during DVT prophylaxis by enoxaparin over the course of a 15-day follow-up in septic patients. Enoxaparin 65-75 coagulation factor X Homo sapiens 0-3 19829297-1 2010 OBJECTIVE: The objective of the study was to evaluate anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy. Enoxaparin 93-103 coagulation factor X Homo sapiens 59-68 20441964-2 2010 A fluorogenic anti-factor Xa (anti-FXa) assay has been developed for the determination of unfractionated heparin (UFH), low molecular weight heparins (LMWHs), namely enoxaparin and tinzaparin, and the synthetic heparinoid danaparoid, in commercial human pooled plasma. Enoxaparin 166-176 coagulation factor X Homo sapiens 35-38 19625075-3 2009 Although the dose in cohort 1 and 2 was similar (median 7000 IE BID), a-FXa-activity was significantly larger under enoxaparin than under tinzaparin (e.g. median at V2: 0.70 IU/ml vs. 0.33 IU/ml). Enoxaparin 116-126 coagulation factor X Homo sapiens 72-75 19625075-4 2009 Also, prophylactic enoxaparin exhibited larger a-FXa-activity than tinzaparin (e.g. median at V2: 0.37 IU/ml vs. 0.22 IU/ml). Enoxaparin 19-29 coagulation factor X Homo sapiens 49-52 19625075-9 2009 Minimal bleeding events occurred in 6 patients (2 under tinzaparin, 4 under enoxaparin) and were associated with significantly higher anti-FXa-activity. Enoxaparin 76-86 coagulation factor X Homo sapiens 139-142 19625075-10 2009 In conclusion, although marked differences between tinzaparin and enoxaparin based on anti-FXa-activity were seen, markers of in vivo biological activity such as TFPI and D-dimer were not different. Enoxaparin 66-76 coagulation factor X Homo sapiens 91-94 19102516-7 2009 Therapeutic anti-factor Xa was observed in 85.3% of patients treated with enoxaparin sodium 0.61-0.8 mg/kg/12h, and in 82.6% of patients treated with enoxaparin sodium 0.81-1.1 mg/kg/12h. Enoxaparin 74-91 coagulation factor X Homo sapiens 17-26 19930848-6 2009 It is concluded that enoxaparin resistance, resulting in high levels of factor Xa residual activity, should be considered in patients with recurrent ischaemia. Enoxaparin 21-31 coagulation factor X Homo sapiens 72-81 20339323-3 2009 The effects of increasing amounts of nadroparin, enoxaparin, or unfractionated heparin on the time-course of FXa or FIIa formation were investigated in tissue factor activated platelet-poor plasma using a subsampling technique and chromogenic substrates. Enoxaparin 49-59 coagulation factor X Homo sapiens 109-112 20339323-5 2009 Nadroparin is as efficient as enoxaparin concerning suppression of endogenous FXa or FIIa formation. Enoxaparin 30-40 coagulation factor X Homo sapiens 78-81 19102516-7 2009 Therapeutic anti-factor Xa was observed in 85.3% of patients treated with enoxaparin sodium 0.61-0.8 mg/kg/12h, and in 82.6% of patients treated with enoxaparin sodium 0.81-1.1 mg/kg/12h. Enoxaparin 150-167 coagulation factor X Homo sapiens 17-26